First Description of Novel End-Organ Effects by Speed Modulation Using the Aortix™ Device.
Journal
Case reports in cardiology
ISSN: 2090-6404
Titre abrégé: Case Rep Cardiol
Pays: United States
ID NLM: 101576452
Informations de publication
Date de publication:
2024
2024
Historique:
received:
09
11
2023
revised:
20
03
2024
accepted:
27
03
2024
medline:
2
5
2024
pubmed:
2
5
2024
entrez:
2
5
2024
Statut:
epublish
Résumé
Aortix™ is a novel percutaneous mechanical circulatory support device designed to facilitate diuresis in patients with cardiorenal syndrome. We describe for the first time the development of end-organ hypoperfusion from excess blood acceleration at the nominal setting and demonstrate through temporal-perfusion marker curves, the potential for speed modulation to optimize results. This will inform future device development and investigation of patient-specific device titration.
Identifiants
pubmed: 38695013
doi: 10.1155/2024/7430212
pmc: PMC11062771
doi:
Types de publication
Case Reports
Langues
eng
Pagination
7430212Informations de copyright
Copyright © 2024 Ajay Bhandari et al.
Déclaration de conflit d'intérêts
Bibhu Mohanty is on the speaker's Bureau for Abbot Structural Heart and Boston Scientific, a consultant for W.L. Gore and Associates and Medtronic, and a medical advisory board member for Boston Scientific and Philips Biotel. Bibhu Mohanty received grant support from W.L. Gore and Associates, Medtronic, Edward Lifesciences, and Boston Scientific. Robby Wu is on the speaker's Bureau for Abbott and an eligibility committee member for Endotronix. All authors are employees of the University of South Florida.